CSPC Pharma (01093.HK) announced that the therapeutic biological product type 1 new drug Enlangsubaidan monoclonal antibody injection (trade name: Enshuxing) developed by the group has received conditional approval for listing from the National Medical Products Administration of China. The product is a recombinant anti-PD-1 fully human monoclonal antibody and the indication approved this time is for the treatment of recurrent or metastatic cervical cancer patients with positive PD-L1 expression who have failed prior treatment with platinum-containing chemotherapy.
石藥集團(01093.HK)恩朗蘇拜單抗注射液獲批准上市
Approval granted for the listing of CSPC Pharma's (01093.HK) Enlang Subei monoclonal antibody injection.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.